CoChat
Sign Up
Cited by 75

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

A model of human p210bcr/ABL-mediated chronic myelogenous leukemia by transduction of primary normal human CD34+ cells with a BCR/ABL-containing retroviral vector

Zhao, Robert C., Jiang, Yuehua, Verfaillie, Catherine M.·2001·Blood
DOI 10.1182/blood.v97.8.2406
Open this paper in CoChat — free account

Abstract

Most insights into the molecular mechanisms underlying transformation by the p210BCR/ABL oncoprotein are derived from studies in which BCR/ABL cDNA was introduced into hematopoietic or fibroblast cell lines. However, such cell line models may not represent all the features of chronic myelogenous leukemia (CML) caused by additional genetic abnormalities and differences in the biology of cell lines compared with primary hematopoietic progenitor and stem cells. A primary human hematopoietic progenitor cell model for CML was developed by the transduction of b3a2 BCR/ABL cDNA in normal CD34+cells. Adhesion of BCR/ABL-transduced CD34+ cells to fibronectin was decreased, but migration over fibronectin was enhanced compared with that of mock-transduced CD34+ cells. Adhesion to fibronectin did not decrease the proliferation of BCR/ABL-transduced CD34+ cells but decreased the proliferation of mock-transduced CD34+ cells. This was associated with elevated levels of p27Kip in p210BCR/ABL-expressing CD34+ cells. In addition, the presence of p210BCR/ABLdelayed apoptosis after the withdrawal of cytokines and serum. Finally, significantly more and larger myeloid colony-forming units grew from BCR/ABL than from mock-transduced CD34+ cells. Thus, the transduction of CD34+ cells with the b3a2-BCR/ABL cDNA recreates most, if not all, phenotypic abnormalities seen in primary CML CD34+ cells. This model should prove useful for the study of molecular mechanisms associated with the presence of p210BCR/ABL in CML.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1182/blood.v97.8.2406

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Research works printed but not linked: 50

  1. Rowley, 1990, The Philadelphia chromosome translocation: a paradigm for understanding leukemia., Cancer., 65, 2178, 10.1002/1097-0142(19900515)65:10<2178::AID-CNCR2820651004>3.0.CO;2-# · DOI
  2. Daley, 1990, Induction of chronic myelogenous leukemia in mice by the P210bcr/abl gene of the Philadelphia chromosome., Science., 247, 824, 10.1126/science.2406902 · DOI · Paper page
  3. Gishizky, 1992, Initiation of deregulated growth of multipotent progenitor cells by bcr-abl in vitro., Science., 256, 836, 10.1126/science.1375394 · DOI
  4. Elefanty, 1990, bcr-abl, the hallmark of chronic myeloid leukaemia in man, induces multiple haemopoietic neoplasms in mice., EMBO J., 9, 10691078, 10.1002/j.1460-2075.1990.tb08212.x · DOI
  5. Li, 1999, The P190, P210, and P230 forms of the BCR/ABL oncogene induce a similar chronic myeloid leukemia-like syndrome in mice but have different lymphoid leukemogenic activity., J Exp Med., 189, 1399, 10.1084/jem.189.9.1399 · DOI
  6. Xiaowu, 1998, Bcr-Abl efficiently induces a myeloproliferative disease and production of excess interleukin-3 and granulocyte-macrophage colony-stimulating factor in mice: a novel model for chronic myelogenous leukemia., Blood., 92, 3829, 10.1182/blood.V92.10.3829 · DOI
  7. Pear, 1998, Efficient and rapid induction of a chronic myelogenous leukemia-like myeloproliferative disease in mice receiving P210 bcr/abl-transduced bone marrow., Blood., 92, 3780, 10.1182/blood.V92.10.3780 · DOI
  8. Salgia, 1997, BCR/ABL induces multiple abnormalities of cytoskeletal function., J Clin Invest., 100, 46, 10.1172/JCI119520 · DOI · Paper page
  9. Salgia, 1996, The related adhesion focal tyrosine kinase forms a complex with paxillin in hematopoietic cells., J Biol Chem., 271, 31222, 10.1074/jbc.271.49.31222 · DOI
  10. Lugo, 1990, Tyrosine kinase activity and transformation potency of bcr-abl oncogene products., Science., 247, 1079, 10.1126/science.2408149 · DOI
  11. Cortez, 1996, The BCR-ABL tyrosine kinase inhibits apoptosis by activating a Ras-dependent signaling pathway., Oncogene., 13, 2589
  12. Jain, 1996, PI 3-kinase activation in BCR/abl-transformed hematopoietic cells does not require interaction of p85 SH2 domains with p210 BCR/abl., Blood., 88, 1542, 10.1182/blood.V88.5.1542.1542 · DOI
  13. Shuai, 1996, Constitutive activation of STAT5 by the BCR-ABL oncogene in chronic myelogenous leukemia., Oncogene., 13, 247
  14. Kantarjian, 1985, Chronic myelogenous leukemia: a multivariate analysis of the associations of patient characteristics and therapy with survival., Blood., 66, 1326, 10.1182/blood.V66.6.1326.1326 · DOI
  15. Marley, 1996, Evaluation of “discordant maturation” in chronic myeloid leukaemia using cultures of primitive progenitor cells and their production of clonogenic progeny (GM-CFU)., Br J Haematol., 95, 299, 10.1046/j.1365-2141.1996.d01-1910.x · DOI
  16. Clarkson, 1997, New understanding of the pathogenesis of CML: a prototype of early neoplasia., Leukemia., 11, 404, 10.1038/sj.leu.2400751 · DOI
  17. Gordon, 1987, Altered adhesive interactions with marrow stroma of haematopoietic progenitor cells in chronic myeloid leukaemia., Nature., 328, 342, 10.1038/328342a0 · DOI
  18. Verfaillie, 1992, Mechanisms underlying abnormal trafficking of malignant progenitors in chronic myelogenous leukemia: decreased adhesion to stroma and fibronectin but increased adhesion to the basement membrane components laminin and collagen type IV., J Clin Invest., 90, 1232, 10.1172/JCI115985 · DOI
  19. Bhatia, 1996, Interferon-alpha restores normal beta 1 integrin-mediated inhibition of hematopoietic progenitor proliferation by the marrow microenvironment in chronic myelogenous leukemia., Blood., 87, 3883, 10.1182/blood.V87.9.3883.bloodjournal8793883 · DOI
  20. Jiang, 2000, Inactivation of the cyclin-dependent kinase inhibitor, p27, is responsible for overriding the integrin-mediated inhibition of CML CD34+ cells., Proc Natl Acad Sci U S A., 97, 10538, 10.1073/pnas.190104497 · DOI
  21. Bedi, 1994, Inhibition of apoptosis by BCR-ABL in chronic myeloid leukemia., Blood., 83, 2038, 10.1182/blood.V83.8.2038.2038 · DOI
  22. Matulonis, 1993, Interleukin-3 and p210 BCR/ABL activate both unique and overlapping pathways of signal transduction in a factor-dependent myeloid cell line., Exp Hematol., 21, 1460
  23. Renshaw, 1995, The human leukemia oncogene bcr-abl abrogates the anchorage requirement but not the growth factor requirement for proliferation., Mol Cell Biol., 15, 1286, 10.1128/MCB.15.3.1286 · DOI
  24. Pui, 1999, Notch1 expression in early lymphopoiesis influences B versus T lineage determination., Immunity., 11, 299, 10.1016/S1074-7613(00)80105-3 · DOI
  25. Naviaux, 1996, The pCL vector system: rapid production of helper-free, high-titer, recombinant retroviruses., J Virol., 70, 5701, 10.1128/JVI.70.8.5701-5705.1996 · DOI
  26. Liu, 2000, Improved retroviral transduction of hematopoietic progenitors by combining methods to enhance virus-cell interaction., Leukemia., 14, 307, 10.1038/sj.leu.2401672 · DOI
  27. Lundell, 1996, Activation-dependent α5β1 integrin-mediated adhesion to fibronectin decreases proliferation of chronic myelogenous leukemia progenitors and K562 cells., Blood., 87, 2450, 10.1182/blood.V87.6.2450.bloodjournal8762450 · DOI
  28. Jiang, 2000, Inactivation of the cyclin-dependent kinase inhibitor, p27, is responsible for overriding the integrin-mediated inhibition of CML CD34+ cells., Proc Natl Acad Sci U S A., 97, 10538, 10.1073/pnas.190104497 · DOI
  29. Zhao, 1997, Gene therapy for chronic myelogenous leukemia (CML): a retroviral vector that renders hematopoietic progenitors methotrexate-resistant and CML progenitors functionally normal and nontumorigenic in vivo., Blood., 90, 4687, 10.1182/blood.V90.12.4687 · DOI · Paper page
  30. Bhatia, 1994, Interferon-alpha restores normal adhesion of chronic myelogenous leukemia hematopoietic progenitors to bone marrow stroma by correcting impaired beta 1 integrin receptor function., J Clin Invest., 94, 384, 10.1172/JCI117333 · DOI
  31. Hurley, 1995, Direct adhesion to bone marrow stroma via fibronectin receptors inhibits hematopoietic progenitor proliferation., J Clin Invest., 96, 511, 10.1172/JCI118063 · DOI
  32. McGahon, 1994, BCR-ABL maintains resistance of chronic myelogenous leukemia cells to apoptotic cell death., Blood., 83, 1179, 10.1182/blood.V83.5.1179.1179 · DOI
  33. Cambier, 1998, BCR-ABL activates pathways mediating cytokine independence and protection against apoptosis in murine hematopoietic cells in a dose-dependent manner., Oncogene., 16, 335, 10.1038/sj.onc.1201490 · DOI
  34. Maguer-Satta, 1998, BCR-ABL accelerates C2-ceramide–induced apoptosis., Oncogene., 16, 237, 10.1038/sj.onc.1201533 · DOI
  35. Marley, 1996, Abnormal kinetics of colony formation by erythroid burst-forming units (BFU-E) in chronic myeloid leukaemia., Br J Haematol., 93, 878, 10.1046/j.1365-2141.1996.d01-1738.x · DOI
  36. Salgia, 1999, The BCR/ABL oncogene alters the chemotactic response to stromal-derived factor-1α., Blood., 94, 4233
  37. Verfaillie, 1996, Benign primitive progenitors can be selected on the basis of the CD34+/HLA-DR− phenotype in early chronic phase but not advanced phase CML., Blood., 87, 4770, 10.1182/blood.V87.11.4770.bloodjournal87114770 · DOI
  38. Verfaillie, 1992, Selection of benign primitive hematopoietic progenitors in chronic myelogenous leukemia on the basis of HLA-DR antigen expression., Blood., 79, 1003, 10.1182/blood.V79.4.1003.bloodjournal7941003 · DOI
  39. Roy, 1999, Expression and function of cell adhesion molecules on fetal liver, cord blood and bone marrow hematopoietic progenitors: implications for anatomical localization and developmental stage specific regulation of hematopoiesis., Exp Hematol., 27, 302, 10.1016/S0301-472X(98)00031-9 · DOI
  40. Lewis, 2000, Multi-lineage expansion potential of primitive hematopoietic progenitors: superiority of umbilical cord blood compared to mobilized peripheral blood., Exp Hematol., 28, 1087, 10.1016/S0301-472X(00)00515-4 · DOI
  41. Lewis, 1998, Establishment of a reproducible model of chronic-phase chronic myeloid leukemia in NOD/SCID mice using blood-derived mononuclear or CD34+ cells., Blood., 91, 630, 10.1182/blood.V91.2.630 · DOI
  42. Wang, 1998, High level engraftment of NOD/SCID mice by primitive normal and leukemic hematopoietic cells from patients with chronic myeloid leukemia in chronic phase., Blood., 91, 2406, 10.1182/blood.V91.7.2406 · DOI
  43. Dazzi, 1998, The kinetics and extent of engraftment of chronic myelogenous leukemia cells in non-obese diabetic/severe combined immunodeficiency mice reflect the phase of the donor's disease: an in vivo model of chronic myelogenous leukemia biology., Blood., 92, 1390, 10.1182/blood.V92.4.1390 · DOI
  44. Rowley, 1982, Chromosome abnormalities in malignant diseases., Adv Cancer Res., 36, 103, 10.1016/S0065-230X(08)60423-6 · DOI
  45. Bhatia, 1998, Inhibition of BCR-ABL expression with antisense oligodeoxynucleotides restores β1 integrin-mediated adhesion and proliferation inhibition in chronic myelogenous leukemia hematopoietic progenitors., Blood., 91, 3414, 10.1182/blood.V91.9.3414 · DOI
  46. Skorski, 1994, Suppression of Philadelphia1 leukemia cell growth in mice by BCR-ABL antisense oligodeoxynucleotide., Proc Natl Acad Sci U S A., 91, 4504, 10.1073/pnas.91.10.4504 · DOI
  47. Leopold, 1996, Multi-unit anti-BCR-ABL ribozyme therapy in chronic myelogenous leukemia., Leuk Lymphoma., 22, 365, 10.3109/10428199609054774 · DOI
  48. Druker, 1996, Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells., Nat Med., 2, 561, 10.1038/nm0596-561 · DOI · Paper page
  49. Druker, 2000, Lessons learned from the development of an abl tyrosine kinase inhibitor for chronic myelogenous leukemia., J Clin Invest., 105, 5, 10.1172/JCI9083 · DOI · Paper page
  50. Bhatia, 1998, Tyrphostin AG957, a tyrosine kinase inhibitor with anti-BCR/ABL tyrosine kinase activity, restores β1 integrin-mediated adhesion and inhibitory signaling in chronic myelogenous leukemia hematopoietic progenitors., Leukemia., 12, 1708, 10.1038/sj.leu.2401193 · DOI

Cited by

See all 75

Metadata

Authors
Zhao, R. C., Jiang, Y., & Verfaillie, C. M.
Affiliations
From the Department of Medicine, Stem Cell Institute, and Cancer Center, University of Minnesota, Minneapolis.
Venue
Blood
Publisher
American Society of Hematology
Published
2001-04-15
Volume
97
Issue
8
Pages
2406-2412
ISSN
  • 1528-0020
  • 0006-4971
DOI
10.1182/blood.v97.8.2406
Cited by
75
References
1
Language
en

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review